Loading...
•
Jun 30, 2021
Royalty Pharma Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts.
Key Takeaways
Royalty Pharma reported a 9% increase in total income and other revenues to $555 million. Adjusted Cash Receipts increased 3% to $475 million, and Adjusted Cash Flow grew 16% to $429 million. The company also raised its full-year 2021 guidance for Adjusted Cash Receipts to $2,080 to $2,120 million.
Net cash provided by operating activities increased to $532 million.
Total income and other revenues grew 9% to $555 million, primarily driven by newly acquired assets.
Adjusted Cash Receipts increased 3% to $475 million, driven by the CF franchise royalty receipts, Biohaven payments and royalty acquisitions.
Adjusted Cash Flow grew 16% to $429 million, reflecting a 90.2% margin.
Revenue by Segment
Forward Guidance
Royalty Pharma expects Adjusted Cash Receipts to be between $2,080 million and $2,120 million, excluding new transactions announced after the date of this release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...